У нас вы можете посмотреть бесплатно Dr. Ciro Franzese on SBRT and Single-Fraction RT in Prostate Cancer | ESTRO 2025 или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
At ESTRO 2025, Prof. Ciro Franzese, Radiation Oncologist at Humanitas San Pio X and Associate Professor at Humanitas University in Milan, presented two key updates in prostate cancer radiotherapy. ✅ In the OLIGOCARE trial interim analysis, involving over 2,000 oligometastatic patients, he showed that combining SBRT with systemic therapies (including chemo, immunotherapy, hormonal, or targeted therapy) does not increase the risk of severe toxicity, supporting its safety in real-world multimodal settings. ✅ In his second presentation, Prof. Franzese explored the emerging role of single-fraction SBRT for localized prostate cancer. Early results from trials like ONE-SHOT, PROSINT, and ABRU indicate comparable disease control and low toxicity compared to conventional 5-fraction SBRT, with potential benefits for elderly or frail patients. ✅ He also highlighted promising data from the POPART trial, which investigates SBRT after prostatectomy as a salvage option, showing encouraging early oncologic and toxicity outcomes. #ESTRO2025 #SBRT #ProstateCancer #OligometastaticCancer #OligoCare #StereotacticRadiotherapy #RadiationOncology #SingleFractionSBRT #HumanitasUniversity SUBSCRIBE to get the latest #oncodaily / @oncodailytv Visit the OncoDaily Website : https://oncodaily.com Like OncoDaily on LinkedIn: / oncodaily Like OncoDaily on X (Twitter): https://x.com/oncodaily Follow OncoDaily on Instagram: / oncodailynews Follow OncoDaily on TikTok: / oncodaily Like OncoDaily on Facebook: / oncodaily SUBSCRIBE to OncoDaily Newsletter: https://oncodaily.com/submit-newsletter About OncoDaily OncoDaily is a world-leading oncology media platform, which is based in the United States and features the cancer related latest news, insights, and patient stories from around the globe. The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”